FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly to endocrinology, and can be used for treating diffuse toxic goiter. 1-3 courses of sclerotherapy are performed every 2 months, during which 0.2-0.3 ml of 3% ethoxysclerol solution is introduced into each lobe of the thyroid gland under ultrasound control. Before the beginning of the sclerotherapy course, thyrostics in tablets are taken orally.
EFFECT: method provides higher effectiveness of treatment of diffuse toxic goiter without application of surgical intervention and radiation therapy due to combination of techniques of the declared invention.
1 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING ENDOCRINE AUTOIMMUNE OPHTHALMOPATHY | 2024 |
|
RU2819981C1 |
| METHOD FOR PREDICTION OF CLINICAL COURSE OF ENDOCRINE OPHTHALMOPATHY IN PATIENTS WITH GRAVES DISEASE BY DETECTING ANTI-THYROID PEROXIDASE ANTIBODIES | 2011 |
|
RU2460072C1 |
| METHOD FOR PERSONALIZED APPROACH TO CHOOSING METHOD FOR TREATMENT OF GRAVES DISEASE | 2022 |
|
RU2794815C1 |
| METHOD OF TREATING HYPOTHYROIDISM WITH DALARGIN | 2023 |
|
RU2814749C1 |
| METHOD FOR PREDICTING RADIOIODINE THERAPY FOR GRAVES' DISEASE | 2022 |
|
RU2791390C1 |
| METHOD FOR PREDICTING THE DEVELOPMENT OF RELAPSE IN THE MEDICAL TREATMENT OF GRAVES' DISEASE | 2021 |
|
RU2778614C1 |
| METHOD OF TREATING BENIGN PARATHYROID GROWTHS | 2023 |
|
RU2813943C1 |
| METHOD AND MEANS OF LIPS OF MOUTH CORRECTION | 2023 |
|
RU2825521C1 |
| METHOD FOR DETERMINING INDIVIDUAL ACTIVITY OF 131-IODINE FOR RADIOIODINE THERAPY OF THYROTOXICOSIS AND PREDICTION OF TIME FOR ACHIEVING A SAFE LEVEL OF 131-IODINE ACTIVITY IN THE PATIENT'S BODY AFTER ADMINISTERING INDIVIDUAL 131-IODINE ACTIVITY | 2019 |
|
RU2722568C1 |
| METHOD FOR DIFFUSE TOXIC GOITER COMPLEX TREATMENT | 2016 |
|
RU2614850C1 |
